Overview

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Status:
Not yet recruiting

Trial end date:
2027-05-10

Target enrollment:

Participant gender:

Summary

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Hypoglycemic Agents
Tirzepatide